Nona Biosciences’ Post

🔊 Weekly round-up!   🧫Finding the right CDMO partner for cell line development Vice President of Mammalian Cell Line Development Dr Séverine Fagète outlines the signs that a CDMO is the right fit for a company’s CLD partnership.   🧠Investigating antipsychotics in a Parkinson’s disease psychosis model Dr Ross Nicholas Waters, Head of R&D at IRLAB Therapeutics AB, shares how three compounds, including IRLAB's Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.   💊Combatting T-cell tumours with antibody drug conjugates Researchers at the Johns Hopkins Kimmel Cancer Center have developed a novel treatment for T cell leukaemias and lymphomas. One treatment with the anti-TRBC1-SG3249 ADC combination saw cancer elimination within seven days in mouse models.   💉New trivalent vaccine for clade 1 sarbecoviruses The vaccine, developed by researchers from the Georgia Institute of Technology and the University of Wisconsin-Madison, provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.   Click on the links in the comments to read more! 👇   #drugdiscovery #lifescience #drugtargets 

Excited to be a part of the BIO International Convention in San Diego, a melting pot of transformative innovation and cutting-edge science. Alongside Marjorie Sidhoum, our VP of Business Development and Corporate Communication, we're immersed in the energy and enthusiasm of industry pioneers, entrepreneurs and investors - all focused advancing innovation in #biotechnology. At DOMAIN Therapeutics, we're driving innovation in the field of cancer treatment, pioneering novel therapeutic strategies that target GPCR mediated immunosuppression to beat resistance and defeat cancer. The pivotal role of GPCRs in restoring the immune responses against tumors and their modulation within the tumor microenvironment holds an immense potential to improve the efficacy of existing treatments. Our #immunooncology pipeline showcases a range of first-in-class and best-in-class assets. The EP4R antagonist, DT-9081, is progressing successfully through Phase I ascending dose clinical study in patients with advanced recurrent and metastatic solid tumors. Concurrently, our Treg-depleting ADCC/ADCP anti-CCR8 monoclonal antibody, DT-7012, is preparing for Phase I #clinicaltrials, anticipated to begin in early 2025. Additionally, PAR2 Negative Allosteric Modulator, DT-9045, is a first-in-class demonstrating a breakthrough mode of action and solid efficacy package in immuno-oncology. We are committed to revolutionizing GPCR #drugdiscovery and broadening therapeutic options for patients battling resistant cancers.  Join us to explore collaboration opportunities and how we can work together to push the boundaries of cancer treatment! #drugdevelopment #immunotherapy

Happy Friday all - hope you had a fantastic 4th of July! Check out this open access Trends in Pharmaceutical Sciences review by Jessica M. Konen, Haoyi Wu, and Don L. Gibbons, "Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities." https://lnkd.in/gV3pdRMv Abstract: Immune checkpoint blockade (ICB) therapy works by inhibiting suppressive checkpoints that become upregulated after T cell activation, like PD-1/PD-L1 and CTLA-4. While the initial FDA approvals of ICB have revolutionized cancer therapies and fueled a burgeoning immuno-oncology field, more recent clinical development of new agents has been slow. Here, focusing on lung cancer, we review the latest research uncovering tumor cell intrinsic and extrinsic ICB resistance mechanisms as major hurdles to treatment efficacy and clinical progress. These include genomic and non-genomic tumor cell alterations, along with host and microenvironmental factors like the microbiome, metabolite accumulation, and hypoxia. Together, these factors can cooperate to promote immunosuppression and ICB resistance. Opportunities to prevent resistance are constantly evolving in this rapidly expanding field, with the goal of moving toward personalized immunotherapeutic regimens. #drugdiscovery #cancerresearch #tme #icb #hypoxia #metabolism #microbiome #immunotherapy #immunooncology #scientificresearch

🚀 𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐚 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐢𝐧 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 🚀 Summit Therapeutics, Inc. has recently shared encouraging Phase 3 trial data for their experimental drug, 𝐢𝐯𝐨𝐧𝐞𝐬𝐜𝐢𝐦𝐚𝐛, in the treatment of advanced non-small cell lung cancer (NSCLC). This innovative therapy, a 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 targeting both PD-1 and VEGF pathways, has shown remarkable potential when compared to Merck’s Keytruda. 🎯 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬: • 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧-𝐅𝐫𝐞𝐞 𝐒𝐮𝐫𝐯𝐢𝐯𝐚𝐥: Ivonescimab nearly doubled the time tumors remained stable (11+ months vs. 6 months for Keytruda). 📊 • 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦: By simultaneously targeting PD-1 and VEGF, ivonescimab may offer enhanced efficacy in halting tumor growth. 💡 • 𝐑𝐞𝐝𝐮𝐜𝐞𝐝 𝐑𝐢𝐬𝐤: A 49% reduction in cancer progression or death was observed in the trial. 🔄 However, while these results are highly promising, there are still 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐮𝐧𝐤𝐧𝐨𝐰𝐧𝐬: • ❓The study didn’t include the current standard combination of 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚 + 𝐜𝐡𝐞𝐦𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲, which raises questions about the drug’s comparative performance. • 🌍The trial was conducted in China, so the 𝐠𝐞𝐧𝐞𝐫𝐚𝐥𝐢𝐳𝐚𝐛𝐢𝐥𝐢𝐭𝐲 of the results needs further validation. 🔬 𝐅𝐮𝐫𝐭𝐡𝐞𝐫 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 are underway to answer these questions, and the global medical community eagerly awaits more data, including overall survival rates. If successful, ivonescimab could reshape the treatment landscape for lung cancer patients worldwide. #InnovationInOncology #LungCancer #Ivonescimab #ClinicalTrials #CancerResearch #Pharma

Time's ticking to secure your pass for the 3rd Next Generation RNA Therapeutics Summit, returning to Boston this May 7-9! Download the three day program: https://ter.li/c7g6q8 As our expert speakers trailblazing circRNA, saRNA and tRNA development prepare to take centre stage to showcase their latest innovations, we truly cannot wait to kickstart the conversation. 🔸 Hear from 22+ expert speakers to gain an understanding of the field's latest developments and future directions 🔸 Meet and network with fellow next generation RNA experts, from 40+ attending companies 🔸 Accelerate the discovery and development of next generation RNAs with targeted delivery, scalable manufacturing, and validated clinical applications in oncology, immunotherapy, and infectious diseases Secure one of the limited remaining passes: https://ter.li/okda7t #RNA #NextGeneration #circRNA #circularRNA #saRNA #selfamplifyingRNA #tRNA #transferRNA

I am thrilled to be joining the industry leaders, innovators and visionaries from around the globe at the upcoming BIO International Convention taking place in San Diego! Our Chief Scientific Officer Stephan Schann and I are eager to share Domain Therapeutics innovative work in pioneering immunotherapies offering a new hope for cancer patients unresponsive to other treatments. As a leading GPCR #immunooncology company, we are dedicated to revolutionizing cancer treatment by unveiling the full potential of GPCR modulation to beat cancer immunoresistance within the complex tumor microenvironment. Our innovative drug candidates are designed to make a difference, among these: Lead clinical candidate: ✔ DT-9081, a best-in-class EP4R antagonist, this small molecule targets prostaglandin E2 (PGE2) mediated resistance and is moving to Phase II #clinicaltrials. Currently in the pre-IND stage of development: ✔ DT-7012, a best-in-class Treg depleting anti-CCR8 monoclonal antibody that targets Treg mediated resistance and expected to start Phase I trials in early 2025 ✔ DT-9045, a first-in-class PAR2Negative Allosteric Modulator, small molecule with unique immuno-oncology potential Our innovative patient-centric approach enables us to restore immunocompetence and deliver the right medicine to the right sub-population of patients, redefining the future of #precisionmedicine and enhancing cancer treatment options. Keen to hear more about our pioneering work? Let’s connect! Schedule a meeting through the partnering platform. Together, we are unlocking the future of cancer therapies and paving the path to a healthier world through science and innovation. Join us on this journey! #biotechnology #drugdevelopment #partnerships Biotechnology Innovation Organization

THERANOSTIC INCUBATOR - having held the first BRIDGister THINK TANK of an upcoming series of bladder cancer theranostic meetings of experts having been involved in the first radioligand instillation therapy proof of concept worldwide. Exchanging radiopharmaceutical protocols to now expand the capabilities within the NeoBRIDGister network for fast track development of compounds that have to tackle problems when being applied as systemic therapy or require fast proof of efficacy. While having finalized respective clinical phase 2 study protocols and having requests in view of patient recruitement possibilities we are excited to take the next step to improve bladder cancer outcome by molecularly stratified trial designs, which acknowledge anti-hormonal, ADC - based, small molecule and theranostic approaches to exploit Simons two stage designs. Bladder cancer treatment outcomes and algorithms will change fastly after decades of stagnancy - for sure. Get more insights into Real World market developments or apply & participate as member of the NeoBRIDGister network clinical trial sites worldwide, exploit options of development drug candidates or learn more by joining the expert team via info@BladderBRIDGister.com. Meet the experts in person at the DFBK 2024 annual meeting on 23rd an 24th of February in the university of Cologne. or at the Theranostic World Congress in Santiago de Chile on 22nd to 24th March 2024. Learn more and register now via info@BladderBRIDGister.com #nuclearmedicine

In May 2023, we made a significant announcement on the PCC nomination targeting ENPP1 for Cancer Immunotherapy and Hypophosphatasia. This novel approach offers promising solutions for tackling “cold tumors,” which are often resistant to conventional treatments due to poor T cell infiltration. Why ENPP1? ENPP1 (ecto-nucleotide pyrophosphatase) is a key enzyme in the tumor microenvironment, implicated in: Hydrolyzing cGAMP: Downregulating the STING pathway and suppressing innate immune responses. Producing Adenosine: Creating an immunosuppressive environment that hinders anti-tumor immunity. Our Strategy: By inhibiting ENPP1, we aim to: Boost STING Activation: Preserve cGAMP levels to enhance anti-tumor immune responses. Reduce Immunosuppression: Lower adenosine production to foster a more immune-favorable tumor environment. Why It Matters for You: Stay ahead in the pharmaceutical industry with cutting-edge solutions designed to enhance the efficacy of existing treatments and tackle resistance mechanisms. Our comprehensive approach not only targets tumor cells but also optimizes the tumor microenvironment to maximize therapeutic outcomes. Partner with Us: As a leader in pharmaceutical innovation, we are committed to transforming cancer treatment landscapes. Connect with us to explore collaboration opportunities and bring these groundbreaking therapies to those who need them most. Insilico Medicine Join us in revolutionizing cancer therapy and improving patient outcomes! #CancerImmunotherapy #ENPP1 #PharmaInnovation #Biotech #Oncology #Pharmaceuticals #CancerTreatment #Partnerships

🔬 #AACR24 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐚𝐭𝐚 & 𝐒𝐭𝐨𝐜𝐤 𝐌𝐨𝐯𝐞𝐬 📈 At this year's #cancer conference we saw not just pre-clinical, but also new clinical data… Here's a glimpse at some clinical readouts and how stocks reacted 👇  Get updates like this each week → https://lnkd.in/gGSgpiJM Kazia Therapeutics Limited (NASDAQ: KZIA) Readout details: Ph1 initial data of EVT801 Indication: Advanced Solid Tumors Results details: Safety data on first enrolled patients showed no safety alert which allows further dose escalation Elicio Therapeutics (NASDAQ: ELTX) Readout details: Updated Ph1 data from AMPLIFY-201 Indication: Pancreatic & Colorectal cancer Results details: The majority of ELI-002-treated patients tested had antigen spreading where induced T cells targeted additional patient-specific tumor mutations beyond mKRAS & observed to have durable mKRAS-specific T cell response with increased memory T cell phenotype. RAPT Therapeutics (NASDAQ: RAPT) Readout details: Ph2 data of tivumecirnon in combo w/ pembrolizumab Indication: Solid Tumors (NSCLC) Results details: Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status Purple Biotech (NASDAQ: PPBT) Readout details: Ph1/2 study data of NT219 in combo w/ cetuximab Indication: SCCHN Results details: Effectively suppress cancer stem cells (CSC) and promote resistance and tumor recurrence. -- 👋 I'm Dominic Vacchiano, Co-founder of BiopharmIQ by Amp. We provide biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma #aacr24

Cancer Diagnostics Market Worth USD 26.6 billion 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/gyNZzbGp The global cancer diagnostics market size is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5%. The growth in this market is attributed to the increasing incidence of cancer and increasing number of private diagnostic laboratories. #cancerdiagnostics #biopsy #IVD #diagnosticimaging GE HealthCare Becton, Dickinson and Company F. Hoffmann-La Roche Ltd Danaher Corporation Thermo Fisher Scientific Abbott QIAGEN Agilent Technologies Illumina Siemens Healthineers Diasorin Myriad Genetics Hologic, Inc. bioMérieux FUJIFILM Holdings Corporation Quidel Exact Sciences Biocartis NV Cancer Diagnostics, Inc. (CDI) Amoy Diagnostics Bio-Rad Laboratories Bio SB, Inc. Vela Diagnostics CANCER TARGETED TECHNOLOGY LLC CancerIQ DNAmito Genetron Holdings Limited（Genetron Health） Metabiomics Novigenix SA Sienna Cancer Diagnostics - A BARD1 Life Sciences company Verily